Use of Pemetrexed in Breast Cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 9, 2006, Pages 24-28

  Dittrich, Christian ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLIC ACID; GEMCITABINE; LIVER ENZYME; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DYSPNEA; EDEMA; ENZYME BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LUNG METASTASIS; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GLUTAMATES; GUANINE; HUMANS;

EID: 33745192541     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.03.017     Document Type: Article

References (25)

1. Shih C., Grindey G.B., Barnett C.J., et al. Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514. Proc Am Assoc Cancer Res 33 (1992) 411 abstr
2. Shih C., Gossett L., Gates S., et al. LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Multiple folate enzymes inhibition. Ann Oncol 7 suppl 1 (1996) 85 abstr
3. Grindey G.B., Shih C., Barnett C.J., et al. LY231514. A novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res 33 (1992) 411 abstr
4. Hanauske A.R., Chen V., Paoletti P., et al. Pemetrexed disodium. A novel antifolate clinically active against multiple solid tumors. Oncologist 6 (2001) 363-373
5. Niyikiza C., Baker S., Johnson R., et al. MTA (LY231514). Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity. Ann Oncol 9 suppl 4 (1998) 126 abstr
6. Niyikiza C., Hanauske A.R., Rusthoven J.J., et al. Pemetrexed safety and dosing strategy. Semin Oncol 29 suppl 18 (2002) 24-29
7. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
8. Eli Lilly and Company. Clinical Investigator Brochure for LY231514 (2004), Eli Lilly and Company, Indianapolis, IN February
9. Gomez H.L., Santillana S., Vallejos C., et al. A phase II trial of pemetrexed in advanced breast cancer. Clinical response and association with molecular target expression. Clin Cancer Res 12 (2006) 832-838
10. O'Shaughnessy J.A., Clark R.S., Blum J.L., et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane and capecitabine for advanced breast cancer. Clin Breast Cancer 6 (2005) 743-749
11. International Union Against Cancer. In: Sobin L.H., and Wittekind C.H. (Eds). TNM Classification of Malignant Tumours (2002), Wiley-Liss Inc, New York, NY
12. Miles D.W., Smith I.E., Coleman R.E., et al. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37 (2001) 1366-1371
13. Martin M., Spielmann M., Namer M., et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 14 (2003) 1246-1252
14. Spielmann M., Martin M., Namer M., et al. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane. An interim analysis. Clin Breast Cancer 2 (2001) 47-51
15. Llombart-Cussac A., Theodoulou M., Rowland K., et al. A phase II trial of pemetrexed disodium (ALIMTA, LY231514, MTA) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T) (salvage chemotherapy). Breast Cancer Res Treat 64 (2000) 122 abstr
16. Teicher B.A., Chen U., Shih C., et al. Treatment regimen including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6 (2000) 1016-1023
17. Hughes A.N., Lind M., Azzabi A., et al. A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta), multitargeted antifolate. Breast Cancer Res Treat 69 (2001) 286 abstr
18. Paridaens R., Dirix R., Mellaerts N., et al. Phase I study of pemetrexed (ALIMTA) and epirubicin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 79 (2003) 280 abstr
19. Dittrich C., Petruzelka L., Vodvarka P., et al. Pemetrexed and cyclophosphamide in patients with locally advanced or metastatic breast cancer. A phase I study. Proc Am Soc Clin Oncol 22 (2003) 40 abstr
20. Nakagawa K., Kudoh S., Matsui K., et al. A phase I study of pemetrexed supplemented with folic acid (FA) and vitamin B12 (VB12) in Japanese patients with solid tumors. Eur J Cancer 2 suppl (2004) 148 abstr
21. Ma C.X., Steen P., Rowland K.M., et al. A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC). An NCCTG study. J Clin Oncol 22 suppl (2004) 14S abstr
22. Adjei A.A., Erlichmann C., Sloan J.A., et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18 (2000) 1748-1757
23. Kolaric K., and Vukas D. Carboplatin activity in untreated metastatic breast cancer patients-Results of a phase II study. Cancer Chemother Pharmacol 27 (1991) 409-412
24. O'Brien M.E., Talbot D.C., and Smith I.E. Carboplatin in the treatment of advanced breast cancer. A phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 11 (1993) 2112-2117
25. Garin A., Manikhas M., Biakhov M., et al. A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC). Preliminary results. J Clin Oncol 23 suppl (2005) 51S abstr